CGTLive’s Weekly Rewind – October 6, 2023
Review top news and interview highlights from the week ending October 6, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. News and Expert Insights in Rare Cancer Cell Therapy for Rare Cancer Day
In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news and expert insights related to cell therapies in development for these indications.
2. Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
The professor of medicine and pediatrics at Washington University in St. Louis discussed future challenges and exciting research in the sarcoma field.
3. Capricor Aligns With FDA on DMD Cell Therapy CAP-1002's Trial in Type-B Meeting
The company stated that based on the meeting, the trial’s primary end points will remain the same.
4. David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMD
The senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
5. Rocket’s LAD-I Gene Therapy BLA Accepted for Priority Review
The therapy has a PDUFA date of March 31, 2024.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
